China Gene Therapy Market Size & Outlook, 2023-2030
- Biotechnology
- Gene Expression & Gene Therapy
- Gene Therapy Market Outlook
- Gene Expression & Gene Therapy
China Gene Therapy Market, 2018-2030 (US$M)
Global Market
Related Markets
Ask a question about the gene therapy market
China gene therapy market highlights
- The China gene therapy market generated a revenue of USD 237.2 million in 2023 and is expected to reach USD 409.4 million by 2030.
- The China market is expected to grow at a CAGR of 8.1% from 2024 to 2030.
- In terms of segment, adenovirus was the largest revenue generating vector type in 2023.
- Other Vector Type is the most lucrative vector type segment registering the fastest growth during the forecast period.
Gene therapy market data book summary
| Market revenue in 2023 | USD 237.2 million |
| Market revenue in 2030 | USD 409.4 million |
| Growth rate | 8.1% (CAGR from 2024 to 2030) |
| Largest segment | Adenovirus |
| Fastest growing segment | Other Vector Type |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Adenovirus, Other Vector Type |
| Key market players worldwide | Regenxbio Inc, Oxford Biomedical Research, Bristol-Myers Squibb Co, Sanofi SA, Ultragenyx Pharmaceutical Inc, Roche Holding AG ADR, Bluebird bio Inc, Novartis AG ADR, UniQure NV, Cellectis SA, Sangamo Therapeutics Inc, Benitec Biopharma Inc, SiBiono GeneTech, Transgene SA, Gensight Biologics SA, Astellas Pharma Inc |
Other key industry trends
- In terms of revenue, China accounted for 2.8% of the global gene therapy market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan gene therapy market is projected to lead the regional market in terms of revenue in 2030.
- Australia is the fastest growing regional market in Asia Pacific and is projected to reach USD 246.2 million by 2030.
China is the first country to commercially use an approved gene therapy molecule in 2003. Gendicine and Oncorine were approved for commercial use in 2003 and 2005, respectively. These drugs were proven to be effective in the treatment of head & neck cancer and are still being used for the same.
China is also focused on the development of newer therapies, such as gene editing, to cure lung cancer. In 2016, Chinese scientists found a way to cure lung cancer by using gene-editing technology and clinical trials to test the same that was recently initiated.
The drugs were expected to reach the market during the forecast period. Furthermore, global players operating in gene therapy market are collaborating with home-grown companies to expedite their production. For instance, in March 2019, Merck KgaA collaborated with GenScript— a Chinese biotech company—for the manufacturing of plasmids and viral vectors.
Key Regions:U.S., UK, Japan, South Korea, China
No credit card required*
Publish Date: Mar 17, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Gene Therapy Market Scope
Gene Therapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Novartis AG ADR | View profile | 76,057 | Lichtstrasse 35, Basel, Switzerland, 4056 | www.novartis.com |
| Roche Holding AG ADR | View profile | 103,605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | www.roche.com |
| Sanofi SA | View profile | 87,994 | 46, avenue de la Grande Armée, Paris, France, 75017 | www.sanofi.com |
| Bristol-Myers Squibb Co | View profile | 34,100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | www.bms.com |
| UniQure NV | View profile | 480 | Paasheuvelweg 25, Amsterdam, NH, Netherlands, 1105 BP | www.uniqure.com |
| SiBiono GeneTech | View profile | 1001-5000 | Shenzhen, Guangdong, China, Asia | www.sibiono.com |
| Cellectis SA | View profile | 216 | 8, rue de la Croix Jarry, Paris, France, 75013 | www.cellectis.com |
| Astellas Pharma Inc | View profile | 14,484 | 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, Japan, 103-8411 | www.astellas.com |
| Bluebird bio Inc | View profile | 323 | 455 Grand Union Boulevard, Somerville, MA, United States, 02145 | www.bluebirdbio.com |
| Sangamo Therapeutics Inc | View profile | 405 | 501 Canal Boulevard, Richmond, CA, United States, 94804 | www.sangamo.com |
China Gene Therapy Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Gene Therapy Market Outlook will help companies and investors design strategic landscapes.
Adenovirus was the largest segment with a revenue share of 62.39% in 2023.
Horizon Databook has segmented the China gene therapy market based on adenovirus, other vector type covering the revenue growth of each sub-segment from 2018 to 2030.
China is the first country to commercially use an approved gene therapy molecule in 2003. Gendicine and Oncorine were approved for commercial use in 2003 and 2005, respectively. These drugs were proven to be effective in the treatment of head & neck cancer and are still being used for the same.
China is also focused on the development of newer therapies, such as gene editing, to cure lung cancer. In 2016, Chinese scientists found a way to cure lung cancer by using gene-editing technology and clinical trials to test the same that was recently initiated.
The drugs were expected to reach the market during the forecast period. Furthermore, global players operating in gene therapy market are collaborating with home-grown companies to expedite their production. For instance, in March 2019, Merck KgaA collaborated with GenScript— a Chinese biotech company—for the manufacturing of plasmids and viral vectors.
- China Gene Therapy Market Vector Type Outlook (Revenue, USD Million , 2018-2030)
- Lentivirus
- AAV
- RetroVirus & gamma RetroVirus
- Modified Herpes Simplex Virus
- Adenovirus
- Non-viral Plasmid Vector
- Other Vector Type
- China Gene Therapy Market Indication Outlook (Revenue, USD Million , 2018-2030)
- Acute Lymphoblastic Leukemia (ALL)
- Inherited Retinal Disease
- Large B-cell Lymphoma
- ADA-SCID
- Melanoma (lesions)
- Beta-Thalassemia Major/SCD
- Head & Neck Squamous Cell Carcinoma
- Peripheral arterial disease
- Spinal Muscular Atrophy (SMA)
- Others
Reasons to subscribe to Gene Therapy Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Gene Therapy Market Outlook databook
- Our clientele includes a mix of Gene Therapy Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China Gene Therapy Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into China Gene Therapy Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
China Gene Therapy Market, 2018-2030 (US$M)
China gene therapy market statistics, by vector type, 2018-2030 (US$M)
